Targeted therapies for the myeloid leukaemias

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Standard chemotherapy for myeloid leukaemias has limited cure rates.
• Understanding leukaemic biology has enabled targeted treatment development.
• Existing therapies rarely achieve complete remission.

Purpose of the Study:

• To review emerging targeted treatment strategies for myeloid leukaemias.
• To assess the efficacy and potential of novel therapeutic agents.
• To compare targeted therapies with current standard care.

Main Methods:

• Review of targeted agents for acute promyelocytic leukaemia (APL), chronic myelogenous leukaemia (CML), and acute myelogenous leukaemia (AML).
• Analysis of agents including all-trans retinoic acid (ATRA), sodium phenylbutyrate, arsenic trioxide, STI-571, antisense oligonucleotides, bcr-abl vaccines, and anti-CD33 monoclonal antibody conjugates (Y90-HuM195, CMA-676).
• Evaluation of mechanisms like differentiation induction, apoptosis, targeting oncogenic events, and antibody-drug conjugates.

Main Results:

• All-trans retinoic acid (ATRA), sodium phenylbutyrate, and arsenic trioxide have shown success in inducing remission for APL.
• Tyrosine kinase inhibitors (e.g., STI-571) and other strategies target key events in CML.
• Anti-CD33 monoclonal antibody conjugates demonstrate some efficacy in AML.

Conclusions:

• Targeted therapies offer promising, potentially less toxic alternatives to chemotherapy for myeloid leukaemias.
• Preliminary results indicate significant efficacy for several novel agents.
• Further clinical studies are essential to establish these targeted treatments as standard care.